Marshall Wace, LLP Unity Biotechnology, Inc. Transaction History

Marshall Wace, LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.56 - $1.29 $24,432 - $56,282	-43,630 Reduced 6.44%	634,236 $355,000
Q1 2022 May 16, 2022	SELL	$0.72 - $1.86 $154,159 - $398,246	-214,111 Reduced 24.0%	677,866 $759,000
Q4 2021 Feb 14, 2022	BUY	$1.3 - $3.17 $998,218 - $2.43 Million	767,860 Added 618.66%	891,977 $1.3 Million
Q3 2021 Nov 15, 2021	BUY	$2.91 - $4.5 $244,949 - $378,787	84,175 Added 210.74%	124,117 $373,000
Q2 2021 Aug 13, 2021	BUY	$4.15 - $6.3 $165,759 - $251,634	39,942 New	39,942 $186,000
Q2 2020 Aug 13, 2020	SELL	$5.28 - $9.67 $54,869 - $100,490	-10,392 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$5.0 - $7.6 $308,420 - $468,798	-61,684 Reduced 85.58%	10,392 $60,000
Q4 2019 Feb 14, 2020	BUY	$5.99 - $8.38 $205,187 - $287,056	34,255 Added 90.57%	72,076 $520,000
Q3 2019 Nov 14, 2019	BUY	$5.62 - $9.63 $212,554 - $364,216	37,821 New	37,821 $231,000

4.41M

Ticker UBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,036,200
Market Cap $20.6M
Description
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular d...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.